Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204

Executive Summary

• Marvel Biosciences Corp. announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 12,570,656 B2 for its lead molecule MB‑204, granting broad composition‑of‑matter and method‑of‑use claims.
• This is the third major jurisdiction (after Japan and China) to grant a composition‑of‑matter patent for MB‑204, significantly strengthening the company’s IP portfolio and supporting future commercialization, licensing, and partnership opportunities.
• The patented compound, a fluorinated analogue of Istradefylline, has demonstrated superior pre‑clinical pharmacokinetics, toxicology safety, and efficacy in models of autism spectrum disorder, depression, Rett syndrome, and Fragile X.

Key Details

• Patent Information: U.S. Patent No. 12,570,656 B2 titled “Purine Compounds for Treating Disorders,” covering composition‑of‑matter claims for MB‑204 and related methods of use.
• Jurisdictional Coverage: Adds the United States to existing patents in Japan (issued Feb 3 2026) and China (issued Aug 18 2025), creating a tri‑regional protection framework.
• Strategic Impact: Enhances the defensibility and economic value of MB‑204, providing potential long‑term market exclusivity upon regulatory approval and supporting future clinical development, partnership, and licensing negotiations.
• Scientific Highlights:
• MB‑204 is a novel fluorinated analogue of the approved adenosine A2A receptor antagonist Istradefylline (Parkinson’s disease therapy).
• Demonstrated superior pharmacokinetics versus parent compound.
• Completed pre‑clinical toxicology testing with favorable safety profile.
• Showed efficacy in pre‑clinical models of depression, multiple autism models (including Rett syndrome), and is currently being evaluated in Fragile X models.
• Market Context: Approximately 1 in 36 children aged 8 are diagnosed with autism spectrum disorder, underscoring unmet medical need for novel therapeutics.

Notable Quotes

“This is the third major jurisdiction that has granted us a composition of matter patent for our lead molecule MB‑204… Strong intellectual property is one of those key components pharmaceutical partners want to see when looking to consecrate a deal with a company such as Marvel.” – Rod Matheson, CEO, Marvel Biosciences Corp.